{"slideshow_credits": null, "snippet": "A steadily rising number of parents face a wrenching choice about whether to add antipsychotic drugs like Risperdal to stimulants like Adderall to treat children for attention deficit hyperactivity disorder.", "abstract": "Steadily rising number of American families face dilemma of whether to let children take multiple psychotropic drugs to temper their troublesome behavior; many experts worry that use of multiple psychotropics in youngsters has not been explored fully; there is also debate over whether database that lists patients' adverse drug reactions reliably monitors risks of psychotropic drug combinations.", "section_name": "U.S.", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Alan", "role": "reported", "lastname": "SCHWARZ", "rank": 1, "organization": ""}], "original": "By ALAN SCHWARZ", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/11/15/us/one-drug-or-2-parents-see-risk-but-also-hope.html", "lead_paragraph": "A steadily rising number of parents face a wrenching choice about whether to add antipsychotic drugs like Risperdal to stimulants like Adderall to treat children for attention deficit hyperactivity disorder.", "headline": {"main": "One Drug or 2? Parents See Risk but Also Hope ", "print_headline": "One Drug or 2? Parents See Risk but Also Hope"}, "_id": "5466bb7438f0d87f029cd0e9", "word_count": "2243", "multimedia": [{"height": 126, "url": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 405, "url": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-articleLarge.jpg", "legacy": {"xlarge": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "405"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/11/16/us/jpPOLYPHARMACY1/jpPOLYPHARMACY1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-11-15T00:00:00Z", "source": "The New York Times", "news_desk": "National", "keywords": [{"value": "Children and Childhood", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Mental Health and Disorders", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Attention Deficit Hyperactivity Disorder", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Adderall (Drug)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "6"}, {"value": "Psychiatry and Psychiatrists", "name": "subject", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}